Discussion
Blood levels of three biomarkers — clusterin (CLU), neurofilament light chain (NfL), and low-density lipoprotein cholesterol (LDL-C) — may help identify cognitive impairment and assess its progression in people with Parkinson’s disease, a study suggests. A model combining the three blood markers with measures of motor disease severity was…
